黑料网

EMAIL: silvia_kreda@med.unc.edu

PERSONAL WEBSITE: /marsicolunginstitute/directory/silvia-m-kreda-phd/

PUBLICATIONS:

Dr. Kreda鈥檚 lab studies mechanisms of delivery of therapeutic molecules in the lung and other extra-hepatic organs. The main goal is to develop novel and efficacious delivery strategies of therapeutic nucleic acids in obstructive lung diseases. The Kreda lab is currently involved in designing an efficacious oligonucleotide-based therapeutic approach to correct cystic fibrosis (CF) mutations in patients resilient to modulator therapies (see Press release June 2021 [https://news.unchealthcare.org/2021/06/scientists-demonstrate-promising-new-approach-for-treating-cystic-fibrosis/]) and orphan mutations that cause primary ciliary dyskinesia (PCD) (see the following press releases:
[ /medicine/silvia-m-kreda-to-study-novel-therapeutic-strategy-for-primary-ciliary-dyskinesia/ ],
[ ). The lab uses state-of-the art technologies and patient-oriented models for precision and personalized medicine approaches.

Dr. Kreda鈥檚 research focuses also on identifying signaling molecules/pathways that regulate airway mucin secretion. The main goal is to uncover potential targets of clinical interest to control abnormal luminal mucus accumulation in lung diseases. Her lab has developed and optimized in vitro and in vivo models of lung diseases with excessive mucus production and quantitative assays for therapeutic drug testing and evaluation of mucin production in airway epithelia.

Dr. Kreda鈥檚 research is fully funded by competitive grants from different sources including the National Institutes of Health (NIH), Cystic Fibrosis Foundation, NCTraCS (the NIH CTSA at 黑料网-CH), Eshelman Institute for Innovation, Initos Pharmaceuticals, AstraZeneca, and Forest Research Institute (now AstraZeneca). Her lab has successful collaborations with scientists from academic and pharmaceutical institutions to develop and test novel drugs for their potential therapeutic use in obstructive lung diseases.